Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

Sauveur-Michel Maira,1 Frédéric Stauffer,1 Josef Brueggen,1 Pascal Furet,1 Christian Schnell,1 Christine Fritsch,1 Saskia Brachmann,1 Patrick Chène,1 Alain De Pover,1 Kevin Schoemaker,3 Doriano Fabbro,2 Daniela Gabriel,2 Marjo Simonen,2 Leon Murphy,4 Peter Finan,4 William Sellers,5 and Carlos García-Echeverría1

1Oncology Disease Area and 2Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Basel, Switzerland; 3Novartis Vaccines and Diagnostics, Inc., Emeryville, California; and 4Developmental and Molecular Pathways and 5Oncology Disease Area, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin inhibitor (mTOR) pathway is often constitutively activated in human tumor cells, providing unique opportunities for anticancer therapeutic intervention. NVP-BEZ235 is an imidazo[4,5-c]quinolinederivative that inhibits PI3K and mTOR kinase activity by binding to the ATP-binding cleft of these enzymes. In cellular settings using human tumor cell lines, this molecule is able to effectively and specifically block the dysfunctional activation of the PI3K pathway, inducing G1 arrest. The cellular activity of NVP-BEZ235 translates well in vivo models of human cancer. Thus, the compound was well tolerated, displayed disease stasis when administered orally, and enhanced the efficacy of other anticancer therapies.

Introduction

Phosphatidylinositol 3-kinase (PI3K) and its downstream effector Akt are frequently deregulated in human cancers (1). To be fully active, Akt needs to be phosphorylated on two critical residues: Thr308 (T308-Akt) and Ser473 (S473-Akt). The upstream kinase responsible for the T308 site phosphorylation is PDK1. The identity of the kinase responsible for the S473 phosphorylation (PDK2) has been a matter of debate as many candidates, including Akt itself, ILK, PDK1, or DNA protein kinase (DNA-PK), have been proposed (2). Compelling evidence have emerged recently that indicate that the rapamycin-insensitive mammalian target of rapamycin inhibitor mTORC2 complex (mTOR in complex with rictor, Sin1, and mLst8) is PDK2 (3–7).

Once activated, Akt phosphorylates several substrates involved in various cellular processes including cell growth, proliferation, survival, and metabolism (8). All of these cellular processes are being considered as crucial features for the establishment and the maintenance of the tumorigenic phenotype (9). Overactivation of the PI3K pathway could be the result of different genetic alterations (10). First, systemic sequencing of the PIK3CA gene has revealed the presence of somatic mutations (11), occurring along the coding region of the gene but with most of them present in two hotspots. The first one is located in the helical domain (with a preponderance for the E545K mutation), and the second one in the kinase domain (with a preponderance for the H1047R mutation). When overexpressed, the corresponding mutant proteins have been found to be oncogenic in vitro and in vivo (12–14). Genetic ablation of the PI3K mutant allele in the colorectal cancer cell lines HCT116 and DLD-1 reduced their oncogenic properties (15).

Second, the PI3K antagonistic dual protein/lipid phosphatase PTEN has been found inactivated or deleted in a large fraction of advanced human cancer, including glioblastoma, endometrial, breast, thyroid, prostate cancer, and melanoma. PTEN-inactivated tumor cells exhibit elevated Akt kinase activity due to uncontrolled phosphorylation of T308 and S473. Under some circumstances, the Ras oncopene or activated receptor tyrosine kinases have also been shown to mediate their transforming potential through aberrant PI3K signaling (16). Regardless of the mechanism, the prevalence of PI3K/Akt signaling abnormalities in human tumors suggests an important role for

Received 1/8/08; revised 3/6/08; accepted 4/3/08.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Sauveur-Michel Maira, Oncology Disease Area, Novartis Institutes for Biomedical Research, Novartis Pharma AG, CH4002 Basel, Switzerland. Phone: 41-61-69-67910; Fax: 41-61-69-65571.

E-mail: sauveur-michel.maira@novartis.com

Copyright © 2008 American Association for Cancer Research.

doi:10.1158/1535-7163.MCT-08-0017

Mol Cancer Ther 2008;7(7):1851–63

Published OnlineFirst July 7, 2008; DOI: 10.1158/1535-7163.MCT-08-0017

Published on April 10, 2017. © 2008 American Association for Cancer Research.
this pathway in cancer pathogenesis and furthermore provides strong support for the development of targeted therapeutic anticancer application of agents that inhibit the activation of the PI3K/Akt pathway.

To date, modulators of the PI3K family have only provided proof-of-concept in preclinical settings. The first-generation PI3K inhibitors include the viridin soil bacteria product wortmannin (17) and LY294002, a morpholino-derivative of quercetin (18). Although suffering from unfavorable pharmaceutical properties, toxicity, and crossover inhibition of other lipid and protein kinases (19), they have been extensively used as tool compounds against a variety human tumor histotypes in vivo and showed the potential utility of PI3K inhibitors as cancer therapeutics (20–22).

In an initial medicinal chemistry effort to develop PDK1 inhibitors using the imidazo-quinoline scaffold, lead compounds were found to also inhibit class I PI3K (23). Further optimization for class I PI3K inhibition using a structure-based design approach led to the identification of NVP-BEZ235, a dual pan-class I PI3K and mTOR kinase inhibitor. We report herein the biochemical and cellular characterization of NVP-BEZ235, showing its potency and selectivity for efficient PI3K pathway blockade. Finally, its antitumor activity in experimental cancer models, including in vivo PK/PD tumor tissue correlations, is reported.

Materials and Methods
Chemical Compounds
NVP-BEZ235 was synthesized in the Global Discovery Chemistry Group (Novartis Pharma, Novartis Institutes for Biomedical Research Oncology) and provided as a 10 mmol/L stock solution in 100% DMSO. Working solutions were prepared freshly before addition to the cell media. Final DMSO concentration was kept constant at 0.1% in control and compound-treated cells. Wortmannin and LY294002 were from Alexis Biochemicals.

In vitro Protein Kinase, PI3K, and mTOR Assays
All the biochemical in vitro protein kinase assays shown in Table 1 were already described (24). PI3Kα, β, and δ proteins were composed of the iSH2 domain of p85 NH2-terminally fused to the full-length protein p110 protein, with the exception of α that also did not contain the last 20 amino acids. PI3Kγ was produced as full-length protein deleted for its first 144 amino acids (25). All constructs were fused to a COOH-terminal His tag for convenient purification and then cloned into the pBlue Bac4.5 (for α, β, and δ isoforms) or pVL1393 (for γ isoform) plasmids. The different vectors were then cotransfected with BaculoGold WT genomic DNA using methods recommended by the vendor for production of the respective recombinant baculoviruses and proteins. Compounds were tested for their activity against PI3K using a Kinase-Glo assay (26). The kinase reaction was done in 384-well black plate (Corning). Each well was loaded with 50 nL of test items (in 90% DMSO) and 5 μL reaction buffer [10 mmol/L Tris-HCl (pH 7.5), 50 mmol/L NaCl, 3 mmol/L MgCl2, 1 mmol/L DTT, and 0.05% CHAPS] containing 10 μg/mL PI substrate ([γ-32P]phosphatidylinositol; Avanti Polar Lipids; prepared in 3% octyl-glucoside) and the PI3K proteins (10, 25, 10, and 130 mmol/L of p110α, p110β, p110δ, and p110γ, respectively) were then added. The reaction was started by the addition of 5 μL of 1 mmol/L ATP prepared in the reaction buffer and ran for either 60 (for p110α, p110β, and p110δ) or 120 min (for p110γ) and subsequently terminated by the addition of 10 μL Kinase-Glo buffer (Promega). The plates were then read in a Synergy 2 reader (BioTek) for luminescence detection.

Cell Lines and Cell Culture
The highly metastatic human prostate tumor cell line PC3M was obtained from Dr. J. Fiedler (M. D. Anderson Cancer Center). The U87MG glioblastoma tumor line was obtained from Dr. Adrian Merlo (University of Basel). The TSC1-null MEF cell line was obtained from Dr. David Kwiatkowski (Brigham and Women’s Hospital). The

Table 1. Biochemical profile of NVP-BEZ235 against selected protein kinases and class I PI3Ks

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>IC50 (nmol/L)</th>
<th>Enzyme</th>
<th>IC50 (nmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I PI3K</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p110α</td>
<td>4 ± 2 (n = 3)</td>
<td>p110β</td>
<td>75 ± 45 (n = 3)</td>
</tr>
<tr>
<td>p110α-H1047R</td>
<td>4.6 ± 0.8 (n = 3)</td>
<td>p110δ</td>
<td>7 ± 6 (n = 3)</td>
</tr>
<tr>
<td>p110α-E545K</td>
<td>5.7 ± 1.0 (n = 3)</td>
<td>p110γ</td>
<td>5 ± 4 (n = 3)</td>
</tr>
<tr>
<td>Protein kinases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VEGFR1/Flt1</td>
<td>&gt;10,000 (n = 3)</td>
<td>Fak</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>Flt3</td>
<td>&gt;10,000 (n = 3)</td>
<td>Jak2</td>
<td>&gt;10,000/9,000</td>
</tr>
<tr>
<td>HER1/ErbB1</td>
<td>&gt;10,000/8,500</td>
<td>c-Abl</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>IGF1-R</td>
<td>&gt;10,000 (n = 3)</td>
<td>c-Src</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>EphB4</td>
<td>&gt;10,000 (n = 3)</td>
<td>PKA</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>Ret</td>
<td>&gt;10,000 (n = 3)</td>
<td>Akt1/PKBα</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>Tie-2/Tek</td>
<td>&gt;10,000 (n = 3)</td>
<td>PDK1</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>c-Met</td>
<td>&gt;10,000 (n = 3)</td>
<td>V599E-B-Raf</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
<tr>
<td>K650E-EGFR</td>
<td>&gt;10,000 (n = 3)</td>
<td>CDK1</td>
<td>&gt;10,000 (n = 3)</td>
</tr>
</tbody>
</table>

NOTE: In vitro kinase assays were done with the indicated recombinant PI3K lipid or protein kinases in the presence of increasing concentrations of NVP-BEZ235 as described in Materials and Methods. The concentration responsible of 50% inhibition of the activity (IC50) is reported as average ± 1 SD (nmol/L).
colorectal HCT116 and HT29 cell lines and the breast cancer cell line were purchased from the American Type Cell Collection (CCL-247, HTB-38, and HTB-20, respectively). The NIH-3T3 derived NWT21 cell line that stably expresses the insulin-like growth factor-I receptor (IGF-IR) was described elsewhere (24). All the cell lines were cultured at 37°C in a 5% CO2 and 80% relative humidity atmosphere incubator in high-glucose DMEM (Life Technologies) complemented with 10% fetal bovine serum, 2 mmol/L glucose, 1% penicillin-streptomycin, and 1% sodium pyruvate. U2OS-FKHR1 cells were obtained by infecting with the FKHR1-GFP retrovirus (details on the cloning strategy and map of the vector are available on request). Stable expressers were obtained after serial dilution of G418-resistant pools of cells.

Cell Lysate Preparation, Immunoblotting, and Antibodies

For biochemical characterization, 2 × 10⁶ cells were seeded per 10 cm dish. After 18 h, the medium was discarded and replaced with 10 mL fresh medium containing the test items. Unless specified in the figure legend, the incubation period was 30 min. For agonist activation, cells were first starved for 18 h in 9 mL medium containing only 0.05% fetal bovine serum. Then cells were pretreated for 30 min with 1 mL medium containing the test items and subsequently incubated for 10 min with the various agonists (final concentrations: 50 ng/mL IGF-I, Prepro-Tech; 60 ng/mL interleukin-4 Sigma; 1 mmol/L anisomycin, Alomone Labs) for a period of 10 min. Cells were washed twice, lysed, and processed as described by Western blot analysis as described. The primary antibodies used were as follows: anti-S473P-Akt, anti-T308P-Akt, anti-S9P-GSK3β, anti-T389P-p70S6 kinase, anti-YP/TP-extracellular signal-regulated kinase 1/2, anti-YP/TP/p38, and anti-Ser15-p53 antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Santa Cruz; anti-GSK3α/β, anti-Y641P-Stat6, anti-S1981P-ATM, anti-T2609 DNA-PKcs, and anti-T389P-p70S6 antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, anti-T32P-FKHRL1, and anti–platelet-derived growth factor receptor antibodies were from Cell Signaling Technologies; anti-Akt, ant
NVP-BEZ235 Displays Potent Antitumor Activity

follows: the powder was dissolved in NMP on sonication, and the remaining volume of polyethylene glycol 300 was added. The application volume was 10 mL/kg. For analytics, frozen tissues were minced and then homogenized in an equal volume of ice-cold PBS (Sigma) using a Polytron homogenizer (IKA). After acetonitrile precipitation and centrifugation, supernatants were analyzed by reverse-phase high-performance liquid chromatography/UV on a Merck-Hitachi/LaChrom equipment including a Nucleosil 100-5 C18 column. Samples were then eluted with a linear gradient of 10% to 90% (v/v) acetonitrile in water containing 0.05% (v/v) trifluoroacetic acid over a period of 20 min at a flow rate of 1 mL/min. The compounds were detected by UV absorbance at 340 nm, and concentrations were determined by the external standard method using peak heights.

Results

NVP-BEZ235 Potently Inhibits PI3K in an ATP Competitive Manner

The imidazo[4,5-c]quinoline scaffold is able to mimic the H-bond interactions of the adenine moiety of ATP with the hinge region using several binding modes (23). This unique feature makes this chemical template an attractive starting point for a structure-based drug design effort, particularly for targets in which some level of structural information is available. The reported X-ray structure of the kinase domain of p110α (25, 27) and a previously identified dual PDK1/PI3K inhibitor were used as the basis for the design of imidazo[4,5-c]quinoline derivatives with PI3K but not PDK1 inhibitory properties. Medicinal chemistry efforts to optimize drug-like and pharmacologic properties led to the synthesis and identification of NVP-BEZ235 (Fig. 1A).

NVP-BEZ235 was tested against class I PI3K using an ATP depletion (Kinase-Glo) assay (Table 1). Although the compound shows slightly lower activity against the ß parologue (IC50, 75 nmol/L), it can be considered a pan-class I PI3K inhibitor. The compound was also found to be as active against the E545K or H1047R mutant forms of PI3Kα as active against the E545K or H1047R mutant forms of PI3Kα and to poorly inhibit (IC50 > 5 µmol/L) a representative panel of protein kinases, including the PI3K effectors Akt and PDK1 (Table 1). Confirming the low nanomolar potency obtained on PI3Kα, NVP-BEZ235 displayed a 2-log left-shifted inhibition curves when compared with LY294002 (IC50, 2.2 and 4.7 versus 745 and 813 nmol/L, respectively) in two different and additional PI3K biochemical assays (ADP release and MaxSorp assays, respectively) using full-length p85α/p110α protein complex (Supplementary Fig. S1).6

Figure 1B shows NVP-BEZ235 docked in a PI3Kα-based three-dimensional homology model of the kinase domain of PI3Kα, a model that is in agreement with the recently determined PI3Kα three-dimensional structure (28). It is proposed that the compound binds in the ATP-binding cleft of the lipid kinase using three H-bond interactions. The nitrogen atom of the core quinoline ring is involved in a key H-bond interaction with the backbone of the conserved PI3Kα Val1085 (Val1086 in ß) and Ile1087. This canonical interaction with the hinge region is observed for ATP and for all the PI3K-inhibitors for which X-ray cocrystal structures exist (25). The second and third H-bond interactions (dotted lines) involve the backbone of the conserved Asp933 (Asp964 in PI3Kγ) and the side chain of the conserved Ser274 (Ser306 in PI3Kγ). These H-bond interactions are complemented by favorable van der Waals contacts with conserved hydrophobic residues of the ATP catalytic site, including Met272 (Met304 in PI3Kγ), Tyr836 (Tyr837 in PI3Kγ), and Met922 (Tyr953 in PI3Kγ). When tested in presence of increasing ATP concentrations (26 nmol/L to 400 µmol/L; Fig. 1C), the IC50 values for NVP-BEZ235 and LY294002 toward PI3Kα inhibition increased in a linear manner, in agreement with an inhibition by ATP competition.

NVP-BEZ235 Specifically Blocks the PI3K Pathway in Cells

The cellular activity of the compound was assessed using tumor cell lines with a hyperactivated PI3K pathway. When exposed to the U87MG glioblastoma PTEN-negative cell line, NVP-BEZ235 reduced S473P-Akt (Fig. 2A, top) and T308P-Akt (middle) levels in a dose-dependent manner. A similar pattern of inhibition was observed using the PTEN-null PC3M prostate tumor cell line (Supplementary Fig. S2).6 No effects on total Akt protein levels were observed showing that the compound has no effect on protein stability. Quantification of S473-Akt and T308P-Akt levels by ELISA revealed that 50% reduction occurred at a compound concentration of 8.0 ± 3.2 nmol/L (n = 6) and 30 ± 15 nmol/L (n = 31), respectively. Pulse-chase experiments revealed a rapid recovery to basal S473p-Akt level (Fig. 2A, bottom), on compound removal from the medium, showing that the inhibitory activity is reversible.

To determine whether the specificity against PI3K observed in the biochemical profiling translates into cellular settings, the effects of the compound on survival (IGF-I), mitogenic (platelet-derived growth factor and epidermal growth factor), stress (anisomycin), cytokine (interleukin-4) and DNA damage (doxorubicin) regulated signaling pathways were evaluated. At a concentration of 250 nmol/L, NVP-BEZ235 was able to reduce IGF-I-induced S473P-Akt levels below the limit of detection, whereas the phosphorylation of the p85 binding site on IGF-IR (Y1316) was not altered (Fig. 2B). Similar results were obtained with the PI3K inhibitors LY294002 and wortmannin. As expected, RAD001 (mTOR inhibitor) and STI571 (Bcr-Abi inhibitor) were not affecting IGF-I-induced phosphorylation of Akt on Ser473. Moreover, IGF-I-induced activation of the mitogen-activated protein kinase pathway was not altered on treatment with NVP-BEZ235. Similar results were obtained when cells were stimulated with the epidermal growth factor or platelet-derived growth factor (data not shown). Hence, it seems unlikely that

6 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

Published Online First July 7, 2008; DOI: 10.1158/1535-7163.MCT-08-0017.

© 2008 American Association for Cancer Research.

Downloaded from mct.aacrjournals.org on April 10, 2017. © 2008 American Association for Cancer Research.
NVP-BEZ235 inhibits PI3K pathway activation by interfering with the kinase activity of the evaluated receptor tyrosine kinases. At a concentration of 250 nmol/L, NVP-BEZ235 did not inhibit anisomycin-induced phosphorylation of c-Jun NH2-terminal kinase and p38 in NWT-21, U87MG, and A549 cells (Fig. 2C). Thus, under the tested experimental conditions, NVP-BEZ235 did not influence the activity of the c-Jun NH2-terminal kinase/p38 stress pathway components such as the mitogen-activated protein kinase kinase (MKK4 and MKK3/6, respectively), mitogen-activated protein kinase kinase kinase (MEKK1/4 and MLK3/6, respectively), and small GTPases such as Rac and Cdc42 (29). Whereas 250 nmol/L NVP-BEZ235 efficiently blocked interleukin-4-induced S473P-Akt levels, activated Stat6 phospholevels were not affected on treatment, excluding an effect of the compounds on Jak kinases at this concentration (Fig. 2D).

Due to the lack of suitable biochemical assays for ATM or DNA-PK, the activities of NVP-BEZ235 against these enzymes were evaluated using cellular readouts. ATM and DNA-PK are involved in the DNA damage repair machinery. DNA strand breaks induced by DNA-damaging agents potently activate ATM and cause its autophosphorylation (30). ATM and DNA-PK can then phosphorylate downstream effectors like p53 (31). When exposed for 24 h to the topoisomerase II inhibitor doxorubicin, U87MG cells displayed a robust increase in S1981P-ATM autophosphorylation and S15P-p53 levels (Fig. 2E, top). Cotreatment with NVP-BEZ235 had no effect on neither DNA double-strand break–induced ATM activation nor p53 activation. In contrast, under the same experimental conditions, S473P-Akt levels were strongly reduced. The effect on doxorubicin induced on S1981P-ATM or T2609P-DNA-PK autophosphorylation levels were investigated in parallel at
NVP-BEZ235 concentrations of 250 and 1,250 nmol/L (Fig. 2E, bottom). Although the S1981P-ATM autophosphorylation levels were poorly affected at any of the dose tested, only the highest one caused a significant reduction of the T2609P-DNA-PK levels. Hence, these data show that in the range of concentrations of NVP-BEZ235 that significantly affect PI3K signaling (250 nmol/L), the compound does not inhibit ATM or DNA-PK, two protein kinases with a PI3K catalytic domain highly homologous to class IA PI3K.

**Effects of NVP-BEZ235 on Akt Downstream Effectors and mTOR**

Reduced phosphorylation of Akt on treatment with NVP-BEZ235 (250 nmol/L) or the internal reference compounds such as wortmannin (250 nmol/L) or LY294002 (20 μmol/L;
ref. 32) correlated with the inhibition of Akt downstream effectors, such as GSK3β and FKHR1L (FOXO3a; Fig. 3A). In agreement with the Akt-dependent but mTORC1-independent regulation of forkhead factors, no effect on FKHR1L localization was observed with the allosteric mTOR inhibitor RAD001 (33). Consistent with these results, treatment of U2OS cells with NVP-BEZ235 stably expressing a GFP-FKHR1L chimeric protein with NVP-BEZ235 led to its complete nuclear relocalization as shown by the time-dependent increased in the fluorescent signal obtained in the nuclei (Fig. 3B). A similar effect was observed when cells were treated with LY294002, but not with RAD001 or DMSO, for which most of the fluorescence emission remained cytosolic. Complete nuclear translocation was achieved between 9 and 12 min after NVP-BEZ235 addition (Supplementary Fig. S3A). NVP-BEZ235 treatment of U2OS-GFP-FKHR1L cells transiently transfected with a luciferase reporter gene controlled by a forkhead binding elements (34) caused significant and dose-dependent transcriptional activity (50% maximum induction for 76 nmol/L; Supplementary Fig. S3B), showing that once relocalized to the nucleus FKHRL1 can bind DNA and activate transcription.

NVP-BEZ235 significantly reduced the phosphorylation levels of the mTOR activated kinase p70S6k (Fig. 3A). This kinase is activated by the TORC1 complex, which itself is relieved from a negative regulation by the TSC1/2 complex in a PI3K- and Akt-dependent manner (35). Cell line lacking functional TSC complexes (TSC1-null MEF) are characterized by a constitutively active mTORC1 complex (36). As expected, TSC1-null MEF exposed RAD001 showed a complete reduction of S235/S236-P-70S6k levels, even at the lowest concentration tested (1 nmol/L). Under similar experimental conditions, NVP-BEZ235 also led to a reduction of S235/S236P-70S6k levels with an IC50 of 6.5 nmol/L (Fig. 3C), suggesting that NVP-BEZ235 can directly inhibit the mTOR kinase, as the kinase domain of mTOR is highly homologous to the one of class IA PI3K.

The activity of NVP-BEZ235 against mTOR was confirmed using a biochemical mTOR K-LISA assay (IC50, 20.7 nmol/L; Supplementary Fig. S4A). To test whether NVP-BEZ235 inhibits both mTORC1 and mTORC2 complexes, immunokinase assays were done using 4E-BP1 (Phas) as a substrate. Maximum activity of TAP-tagged immunoprecipitated Raptor (mTORC1) or Rictor (mTORC2) kinase complexes was reached after an incubation period of 30 min (Supplementary Fig. S4B). NVP-BEZ235 to otherwise similar assay conditions caused a concentration-dependent decrease in mTORC1 and mTORC2 activities (Fig. 3D). Altogether, these data show that NVP-BEZ235 is also a mTORC1/2 catalytic inhibitor.

**NVP-BEZ235 Possesses Strong Antiproliferative Activity**

Both PTEN-null cell lines PC3M and U87MG showed a dose-dependent reduction in cell proliferation when treated with increasing concentrations of NVP-BEZ235, with an average GI50 of 10 to 12 nmol/L. However, no obvious decline in cell viability was observed on treatment with NVP-BEZ235, as the compound was never able to reduce the cell number below the amount originally plated (corresponding to the 0% plateau; Fig. 4A).

Cell cycle analysis of growing PC3M cells revealed that the G1 population increased from 66.4% (DMSO controls) to 74.1% and 92.3% on treatment of the cells with 10 to 50 nmol/L NVP-BEZ235, respectively (Fig. 4B). A similar effect was observed when the cells were treated with LY294002. For both compounds, no clear sub-G1 population could be detected, indicating a limited ability of both inhibitors for cell death induction in this cell line. NVP-BEZ235 incubation significantly increased the amount of the cyclin-dependent kinase inhibitor p27Kip1 in the p53-negative PC3M cell line. Accordingly, p53-regulated gene product levels in basal or treated (DNA-damaging cisplatin agent, LY294002 or NVP-BEZ235) conditions were not detectable in this cell line. A similar study was therefore done in the p53-positive cell line HCT116. As expected, cisplatin but not LY294002 or NVP-BEZ235 treatments increased p21Cip/Waf1 levels, showing that PI3K inhibition does not influence p21Cip/Waf1 protein levels.

**NVP-BEZ235 Is an Orally Available PI3K Inhibitor with Well-Tolerated Antitumor Activity**

The pharmacokinetic properties of NVP-BEZ235 were originally evaluated in PC3M tumor-bearing nude mice. At a dose of 50 mg/kg, NVP-BEZ235 appeared rapidly in plasma with a Cmax of 1.68 μmol/L at 0.5 h and a C24h, of...
In the tumor tissue, the $C_{\text{max}}$ attained was 2.05 nmol/g at 1 h ($T_{\text{max}}$), which decreased to 0.23 nmol/g after 24 h (Fig. 5A). NVP-BEZ235 is eliminated relatively quickly from the liver. In vivo analysis of the S473P-Akt levels in the tumor tissue revealed that maximum inhibition was obtained 1 h after dosing (corresponding to the tumor $C_{\text{max}}$), and persistent inhibition was observed still 16 h after treatment, with almost complete recovery to basal levels obtained in two of four tumors at 24 h after dose (Fig. 5B). Pharmacokinetic simulation based on this study revealed that steady-state levels would be achieved between 3 and 5 days, when dosing either at 50 mg/kg given daily or at 25 mg/kg given twice daily. Differences between the dosage regimens would reside in the predicted tumor peak levels (2.6 versus 1.6 nmol/g, respectively) whereas through levels would remain almost comparable (0.53 versus 0.60 μmol/L, respectively). Taking into consideration this pharmacokinetic simulation, chronic treatment of PC3M tumor-bearing animals was done at 25 mg/kg p.o. NVP-BEZ235 twice daily. Using this schedule, a statistically significant inhibition of tumor growth was observed, with a final T/C value of 22% after 10 days of treatment (Fig. 5C). The treatment was well tolerated as concluded from the nonstatistically significant effect of NVP-BEZ235 on body weight gain (Fig. 5C) and by the fact that none of the animals died during the course of the study. The antitumor effect was well correlated with the inhibition of S473P-Akt in the tumor tissue 1 or 18 h after

Figure 3. Effects of NVP-BEZ235 on Akt downstream effectors and mTOR. A, U87MG cells were treated with the indicated inhibitors for 30 min. Cells were then lysed and cell extracts were analyzed by Western blotting for phosphorylated Akt (both sites), GSK3β, p70S6K, and FKHRL1 (FOXO3A). B, effect of LY294002 (10 μmol/L), NVP-BEZ235 (250 nmol/L), or RAD001 (250 nmol/L) on FKHRL1-GFP translocation. U2OS-GFP-FOXO3A cells were incubated for either 1, 2, or 4 h with the compounds and then fixed and the nuclei were stained with Hoechst. The cells were imaged with a standard inverted epifluorescence microscope. C, NVP-BEZ235 inhibits mTORC1 activity in cells. TSC1-null MEF cells were incubated with increasing doses of either RAD001 or NVP-BEZ235 for 1 h. Cells were then fixed, blocked, and stained with the anti-phospho-S6 (Ser235/Ser236). D, NVP-BEZ235 inhibits mTORC1 and mTORC2. IgG-Sepharose pull-downs of HeLa cells stably expressing either TAP-tagged Rictor (500 μg) or TAP-tagged Raptor (30 μg) were subjected to in vitro kinase assays with 4EBP1 (Phas) as a substrate for 30 min (TAP-Rictor) or 20 min (TAP-Raptor) at 30°C with increasing amounts of NVP-BEZ235. Kinase reactions were analyzed by Western blotting to assess inhibition on Ser37/Ser46 phosphorylation of 4EBP1.
the last dose detected either by Western blotting of tumor extracts or by immunostaining of tumor sections (Fig. 5D). Compound concentrations at these time points were 1.32 nmol/g at 1 h and 0.51 nmol/g at 18 h, close to the predicted values for steady-state peak levels (see above).

Activation of the PI3K pathway through loss of PTEN function in glioblastoma multiforme has been correlated with resistance to epidermal growth factor receptor--targeted therapies (37), radiotherapy, and alkylating agents such as temozolomide (38). It is therefore anticipated that PI3K inhibitors might be beneficial in the treatment of this malignancy. To assess the antitumor activity of NVP-BEZ235 against a PTEN-null glioblastoma multiforme tumor model, s.c. U87MG tumor-bearing animals were treated either with NVP-BEZ235 alone or in combination with the standard of care temozolomide (39). As a single agent, a dose-dependent effect on tumor growth was observed when animals were treated with suboptimal (25 mg/kg/d once per day) to optimal (45 mg/kg/d once per day) doses of NVP-BEZ235 (Fig. 6A), with almost tumor stasis achieved at the highest dose tested (T/C of 22%, 18%, and 5.5%, at 25, 35, and 45 mg/kg, respectively). No body weight loss was observed during the course of the experiment in all groups (Fig. 6A). The antitumor activity was in this model also well correlated with reduction in S473P-Akt levels in the tumor (Fig. 6B). Because the activation of PI3K pathway is linked to survival, PI3K inhibitors would be ideal candidates for combination therapies. Temozolomide introduces O6-methylguanine adducts in DNA, which mispairs with thymine during the next cell cycle of replication, leading to G2 checkpoint activation and subsequent cell death. Akt activation was shown to bypass the G2 arrest on temozolomide treatment (40), suggesting that Akt inactivation might positively influence temozolomide effects. Treatment of U87MG tumor-bearing animals with temozolomide alone resulted in efficient block of tumor growth (T/C of 5.2%), whereas the addition of NVP-BEZ235 even caused regression of the tumors (69%) without statistically significant effect on body weight gain (Fig. 6C). Altogether, these preliminary in vivo efficacy results suggest that NVP-BEZ235 causes disease stasis when administered orally as a single agent and can enhance the efficacy of other anticancer agents when used in in vivo combination studies.

Figure 4. Effects of NVP-BEZ235 on proliferation and the cell cycle. A, U87MG and PC3M cells were incubated with increasing amount of NVP-BEZ235 for 72 h. Viable cells were then stained and cell proliferation was estimated with a standard methylene blue staining assay. Cell proliferation is expressed as a percentage of the average difference in cell number observed in NVP-BEZ235-treated cells divided by the average difference observed in untreated controls (100% represents the maximum cell proliferation observed and 0% represents the inoculums; the number of cells at the time in which the compound is added to the medium). B, PC3M cells were incubated with the indicated compound for 24 h. Determination of cell number was then determined by fluorescence-activated cell sorting. C, PC3M and HCT116 cells were incubated for 24 h with the indicated compounds. Cells were then lysed and cell extracts were analyzed by Western blotting for p21(1p1/waf1) and p27(kip1) cyclin-dependent kinase inhibitors.
The prevalence of PI3K signaling abnormalities in human cancer cells has suggested the potential use of PI3K pathway modulators as novel targeted therapeutic agents. Over the past few years, medicinal chemistry activities have been directed to develop pan- or isoform-selective PI3K inhibitors with improved pharmacologic characteristics as well as selectivity profile (41). NVP-BEZ235 is the result of a structure-based design approach from a previously identified dual PDK1/PI3K lead compound. This imidazo-quinoline derivative, which is structurally different from currently available lipid kinase inhibitors

**Figure 5.** Pharmacokinetic/pharmacodynamic relationship in tumor-bearing animals. A and B, PC3M tumor-bearing animals ($n = 4$) were treated orally with 50 mg/kg NVP-BEZ235, and animals were sacrificed 1, 2, 6, 16, and 24 h after dosing. Compound concentration in plasma, liver, and tumor (A) was determined by high-performance liquid chromatography/UV (sensitivity, 0.1 μmol/L). In parallel, tumor extracts were used to determine activated Akt levels determined by Western blotting (B). C and D, PC3M tumor-bearing animals were treated orally with NVP-BEZ235 twice daily with a dose of 25 mg/kg for 10 d. Tumor volumes were callipered and body weight was measured during the course of the experiment (C). Animals were sacrificed either 1 or 18 h after last dose, and tumor was removed and analyzed as described in B (top) or sections were analyzed by immunostaining (bottom) with an anti-S473P-Akt antibody (D). *, $P < 0.05$, one-way ANOVA with Dunnett’s post hoc test.

**Discussion**

The prevalence of PI3K signaling abnormalities in human cancer cells has suggested the potential use of PI3K pathway modulators as novel targeted therapeutic agents. Over the past few years, medicinal chemistry activities have been directed to develop pan- or isoform-selective PI3K inhibitors with improved pharmacologic characteristics as well as selectivity profile (41). NVP-BEZ235 is the result of a structure-based design approach from a previously identified dual PDK1/PI3K lead compound. This imidazo-quinoline derivative, which is structurally different from currently available lipid kinase inhibitors.
(42–44), exhibits a high degree of inhibitory activity for the four PI3K paralogues. The compound is also active against the most common PI3Ka mutants and mTOR.

Docking studies using a PI3Kα homology model have suggested an intricate network of H-bond interactions involving the PI3Kα paralogue conserved residues Val^{851}, Asp^{933}, and Ser^{774}. These H-bond interactions, together with the potential multiple van der Waals contacts established with conserved hydrophobic residues of the ATP-binding cleft, may account for its potency against PI3K and selectivity profile over protein kinases. Although the interactions with the catalytic site of mTOR was not investigated in detail, systematic docking of the inhibitor in a homology model of mTOR generated as described for PI3Kα (see legend of Fig. 1B) suggests similar binding modes of the compound for these two kinases, particularly with a potential H-bond with the side chain of Ser^{2165} in mTOR (equivalent to Ser^{774} in PI3Kα). Enzyme kinetic analyses showed that NVP-BEZ235 inhibits human PI3Kα competitively with respect to ATP. Cocrystallization studies and single amino acid PI3K mutations are currently ongoing to confirm the preceding molecular modeling predictions.

Compound treatment entailed a decrease in T308P-Akt and S473P-Akt levels as shown by Western blot and ELISA analyses. Using PH domain knock-in mutations, the Akt-mediated PDK1 phosphorylation was shown to be PI3K dependent (45). Several pieces of evidence suggest that the PDK2 activity is primarily due to the mTORC2 complex and that this enzyme has no influence on the phosphorylation of Thr^{308} (4, 46). Hence, inhibition of T308P-Akt levels argues for a direct inhibition of PI3K by

---

**Figure 6.** Effects of NVP-BEZ235 against experimental glioblastoma tumor model. U87MG tumor-bearing animals were treated with either NVP-BEZ235 alone (A–C) or in combination with temozolomide (C) at the indicated doses and schedules. Tumor volumes were callipered and body weight was measured during the course of the experiment (A and C). One hour after last dose, the animals were sacrificed and tumor was removed and analyzed as described in Fig. 5B (B). *, P < 0.05, one-way ANOVA with Dunnett’s post hoc test.
NVP-BEZ235. However, the lower IC_{50} value obtained for the Ser^{473} levels is unlikely to be due to the sole effect on PI3K but rather to the concomitant blockade of PI3K and mTORC2. Consistent with abrogation of Akt function, decrease in S9 protein kinase levels, nuclear localization of FKHR1, and forkhead-mediated transcription were induced by NVP-BEZ235. The fact that NVP-BEZ235 was more efficient than LY294002 to block Akt activation likely reflects, once more, the synergistic inhibitory effects on PI3K and mTORC2. Systematic analyses of components of different signal transduction pathways (IGF-1, epidermal growth factor, platelet-derived growth factor, interleukin-4, DNA damage, and stress induced) showed that the effects displayed by NVP-BEZ235 are due to selective PI3K/mTOR pathway inhibition, as no inhibitory effects were observed on PI3K independent readouts.

Treatment of U87MG cells with NVP-BEZ235 resulted in a robust growth arrest in the G_{1} phase with no apoptosis induction. A similar observation has been reported for other PI3K modulators (43, 44). Although this result might suggest that inhibition of the PI3K pathway per se is not sufficient to drive cells into apoptosis, we cannot exclude that induction of apoptosis could happen with other cell lines or in in vivo settings. Hence, when concomitantly challenged with certain cytotoxic agents or targeted agents, PI3K inhibition would be important to prime the cells to enter programmed cell death. The G_{1} arrest observed with NVP-BEZ235 in PC3M seems to be well correlated with the induction of the p27kip1 cyclin-dependent kinase inhibitor. These data are in agreement with the fact that p27kip1 is a target gene for forkhead factors and that NVP-BEZ235 rapidly induces forkhead factor nuclear translocation. Although the effect seems to not require p27kip1, we cannot exclude that the latter would still be critical in other cell lines.

NVP-BEZ235 displayed a statistically significant antitumor activity against the PTEN-null U87MG and PC3M tumor xenografts. The in vivo tumor growth inhibition of NVP-BEZ235 activity was dose dependent, and the observed effect on S473P-Akt levels correlated with the amount of compound present in the tumor tissue. Because the amount of compound present in the tumor tissue is unlikely to be due to the sole effect on PI3K, it is likely that mTOR inhibition is also contributing to the antitumor activity of the compound. Due to a negative feedback loop involving the phosphorylation of p70S6K, inhibition of mTORC1 activity alone could result in the enhanced activation of the PI3K axis (49). Exposure to a dual catalytic PI3K/mTOR inhibitor such as NVP-BEZ235 might therefore be sufficient to avoid PI3K pathway reactivation.

In conclusion, NVP-BEZ235 is a dual pan-PI3K/mTOR inhibitor obtained after an extensive medicinal chemistry effort to modulate the biological activity and pharmacological properties of imidazol[4,5-c]quinoline-based compounds. NVP-BEZ235 effectively blocks the dysfunctional activation of the PI3K pathway in cellular and in vivo settings. The compound displayed diseases stasis in relevant in vivo models of human cancer when given orally and enhanced the antitumor activity of other cancer agents. NVP-BEZ235 displays all the features required for clinical development and has entered phase I clinical trials in cancer patients.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Marc Hattenberger, Melanie Muller, Fabian Stauffer, Juliane Vaxelaire, Malika, Kazic, Yvonne Ibig-Rehm, and Vincent Unterreiner for excellent technical assistance; Dr. Robert Cozens for critical review of this article; and Dr. David Kwiatkowski for the TSC1/2-null MEP.

References


McManus EJ, Collins BJ, Ashby PR, et al. The role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knocking mutation. EMBO J 2004;23:2071 – 82.


Molecular Cancer Therapeutics

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent *in vivo* antitumor activity

Sauveur-Michel Maira, Frédéric Stauffer, Josef Brueggen, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-08-0017

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2008/08/13/1535-7163.MCT-08-0017.DC1

Cited articles
This article cites 49 articles, 22 of which you can access for free at:
http://mct.aacrjournals.org/content/7/7/1851.full.html#ref-list-1

Citing articles
This article has been cited by 100 HighWire-hosted articles. Access the articles at:
/content/7/7/1851.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.